Research and development
The science of Tumor Treating Fields has the potential to extend beyond glioblastoma and mesothelioma. Tumor Treating Fields have shown a consistent anti-mitotic effect in our preclinical and clinical research spanning more than two decades.
We believe we have gained a deep understanding of the underlying mechanism of action and the multiple pathways through which Tumor Treating Fields extert their effects within dividing cancer cells. Our research shows that Tumor Treating Fields can have an anti-mitotic effect in more than 15 different solid tumor types in culture and in several in vivo tumor models, including some of the most aggressive forms of cancer. We are committed to advancing the science of Tumor Treating Fields across a broad spectrum of solid tumors and bringing our therapy to cancer patients who may benefit.
Novocure
clinical pipeline
as of October 2024
We also have pre-clinical data for Tumor Treating Fields in these areas:
breast cancer
colorectal carcinoma
fibrous histiocytoma
malignant melanoma
meningioma
renal adenocarcinoma
urinary transitional cell carcinoma
cervical cancer
ependymoma
gliosarcoma
medulloblastoma
osteosarcoma
small cell lung cancer
uveal melanoma